Pursuant to Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shreekrishna Biotech has informed about the Statement of Investor Complaints for the quarter ended June 30, 2017.
The above information is a part of company’s filings submitted to BSE.